Inhibition of Proliferation of 4T1 Breast Cancer Cells by <i>Cuscuta</i> Alcohol Extract Based on mTOR/HIF-1<i>α</i>/VEGF Signaling Pathway

SONG Hui; HUANG Xiaoqiao; SUN Xiangming; HU Yang; SHAN Wencai; TANG Jing; LI Wenlan

doi:10.13386/j.issn1002-0306.2024050320

Turn off MathJax

Article Contents

Abstract

References

SONG Hui, HUANG Xiaoqiao, SUN Xiangming, et al. Inhibition of Proliferation of 4T1 Breast Cancer Cells by Cuscuta Alcohol Extract Based on mTOR/HIF-1α/VEGF Signaling Pathway[J]. Science and Technology of Food Industry, 2025, 46(7): 1−10. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2024050320.

Citation:

PDF (15126 KB)

Inhibition of Proliferation of 4T1 Breast Cancer Cells by Cuscuta Alcohol Extract Based on mTOR/HIF-1α/VEGF Signaling Pathway

SONG Hui^{1, 2,},
HUANG Xiaoqiao¹,
SUN Xiangming^{1, 2},
HU Yang^{1, 2},
SHAN Wencai¹,
TANG Jing¹,
LI Wenlan^{1, 2, ,}

1.
School of Pharmacy (Engineering Research Center for Medicine), Harbin University of Commerce, Harbin 150076, China
2.
Anti-tumor Natural Drug Engineering Research Center, Ministry of Education, Harbin 150076, China

More Information

Received Date: May 26, 2024
Available Online: February 07, 2025

Graphical Abstract

Abstract

Abstract

Objective: To examine the inhibitory effects and mechanisms of Cuscuta alcohol extract on the proliferation of 4T1 breast cancer cells, both in vitro and in vivo. Methods: MTT, scratch, transwell, and flow cytometric assays were used to examine the effects of Cuscuta alcohol extract on the proliferation, migration, invasion, and apoptosis of 4T1 breast cancer cells in vitro. Additionally, an in vivo 4T1 tumor-bearing mouse model was established. ELISA kits measured TNF-α, IL-2, and IL-10 levels in 4T1 tumor-bearing mice after 14 days of intragastric Cuscuta alcohol extract administration. Concurrently, tumor tissues from both the model mice and the high-dose Cuscuta alcohol extract group were analyzed using transcriptome sequencing to identify differentially expressed genes. GO and KEGG enrichment analyses were conducted, and the Western Blot assays were performed to verify the expression of the mTOR/HIF-1α/VEGF signaling pathway. Results: Cuscuta alcohol extract (400, 800 and 1200 μg/mL) significantly reduced the proliferation, migration, and invasion of 4T1 breast cancer cells (P<0.05, P<0.01), and enhanced their apoptosis (P<0.01), compared to blank control. In the in vivo model, Cuscuta alcohol extract (6.24 and 12.48 g/kg) significantly increased the serum levels of TNF-α, IL-2, and IL-10 in mice relative to model group (P<0.05, P<0.01). Transcriptome sequencing identified 512 differentially expressed genes, including 154 upregulated and 358 downregulated genes. GO enrichment analysis identified 1870 items, while KEGG enrichment analysis enriched for cytokine receptor interactions, HIF-1 signalling pathway, IL-17 signalling pathway and other signalling pathways. The extract reduced the p-mTOR, HIF-1α, p-RPS6K, p-P70S6K, VEGF, and VEGFR2 protein expression levels in tumor tissues in a dose-dependent manner (P<0.05, P<0.01). Conclusions: The alcohol extract of Cuscuta inhibits the proliferation of 4T1 breast cancer cells and increase the serum expression levels of inflammatory factors in mice. Its antitumor mechanism is related to the modulation of the mTOR/HIF-1α/VEGF signaling pathway.
- Cuscuta,
- breast cancer,
- transcriptomics,
- mTOR/HIF-1α/VEGF signaling pathway

FullText(HTML)

References (42)

References

[1]	WEI W, ZENG H, ZHENG R, et al. Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol,2020,21(7):e342−e349. doi: 10.1016/S1470-2045(20)30073-5
[2]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209−249. doi: 10.3322/caac.21660
[3]	WILKINSON L, GATHANI T. Understanding breast cancer as a global health concern[J]. Br J Radiol,2022,95(1130):20211033. doi: 10.1259/bjr.20211033
[4]	BARZEMAN K, KARAMI J, ZAREI Z, et al. Breast cancer:Biology, biomarkers, and treatments[J]. Int Immunopharmacol,2020,84:106535. doi: 10.1016/j.intimp.2020.106535
[5]	GAO J J, CHENG J, BLOOMQUIST E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer:A US Food and Drug Administration pooled analysis[J]. Lancet Oncol,2020,21(2):250−260. doi: 10.1016/S1470-2045(19)30804-6
[6]	KATSURA C, OGUNMWONYI I, KANKAM H K, et al. Breast cancer:Presentation, investigation and management[J]. Br J Hosp Med (Lond),2022,83(2):1−7.
[7]	陈玉洁, 孔祥定, 陈静, 等. 中医药干预乳腺癌肿瘤微环境的研究进展[J]. 河南中医,2021,41(9):1442−1446. [CHEN Y J, KONG X D, CHEN J, et al. Research progress of TCM intervention on tumor microenvironment of breast cancer[J]. Henan Traditional Chinese Medicine,2021,41(9):1442−1446.] CHEN Y J, KONG X D, CHEN J, et al. Research progress of TCM intervention on tumor microenvironment of breast cancer[J]. Henan Traditional Chinese Medicine, 2021, 41（9）: 1442−1446.
[8]	SUN Q, HE M, ZHANG M, et al. Traditional chinese medicine and colorectal cancer:Implications for drug discovery[J]. Front Pharmacol,2021,12:685002. doi: 10.3389/fphar.2021.685002
[9]	王尧尧, 王蕾, 戚莹雪, 等. 菟丝子药材化学成分研究进展[J]. 山东中医药大学学报,2020,44(6):705−712. [WANG Y Y, WANG L, QI Y X, et al. Research progress on chemical constituents of Tusizi(Cuscutae Semen)[J]. Journal of Shandong University of TCM,2020,44(6):705−712.] WANG Y Y, WANG L, QI Y X, et al. Research progress on chemical constituents of Tusizi（Cuscutae Semen）[J]. Journal of Shandong University of TCM, 2020, 44（6）: 705−712.
[10]	国家药典委员会. 中华人民共和国药典 2020 年版(一部)[S]. 北京:中国医药科技出版社, 2020:310. [Chinese pharmacopoeia commission. Pharmacopoeia of the People's Republic of China 2020 (part I)[S]. Beijing:China Medical Science Press, 2020:310.] Chinese pharmacopoeia commission. Pharmacopoeia of the People's Republic of China 2020 （part I）[S]. Beijing: China Medical Science Press, 2020: 310.
[11]	赵宝宝, 李兴勇, 董万涛, 等. 中药菟丝子防治骨质疏松症的研究进展[J]. 中国骨质疏松杂志,2023,29(7):1089−1092. [ZHAO B B, LI X Y, DONG W T, et al. Research progress of traditional Chinese medicine dodder in prevention and treatment of osteoporosis[J]. Chin J Osteoporos,2023,29(7):1089−1092.] doi: 10.3969/j.issn.1006-7108.2023.07.031 ZHAO B B, LI X Y, DONG W T, et al. Research progress of traditional Chinese medicine dodder in prevention and treatment of osteoporosis[J]. Chin J Osteoporos, 2023, 29（7）: 1089−1092. doi: 10.3969/j.issn.1006-7108.2023.07.031
[12]	王莹, 张婧如, 田伟, 等. 菟丝子及其提取物药理机制研究进展[J]. 中国中医基础医学杂志,2023,29(11):1961−1964. [WANG Y, ZHANG J R, TIAN W, et al. Research progress on pharmacological mechanisms of Cuscuta Chinensis and its extracts[J]. Journal of Basic Chinese Medicine,2023,29(11):1961−1964.] WANG Y, ZHANG J R, TIAN W, et al. Research progress on pharmacological mechanisms of Cuscuta Chinensis and its extracts[J]. Journal of Basic Chinese Medicine, 2023, 29（11）: 1961−1964.
[13]	刘绍明. 二仙赞育方治疗弱精子症的临床及作用机制研究[D]. 南京:南京中医药大学, 2022. [LIU S M. Study on the clinical and mechanism of Erxian Zanyu formula in the treatment of asthenospermia[D]. Nanjing:Nanjing University of Chinese Medicine, 2022.] LIU S M. Study on the clinical and mechanism of Erxian Zanyu formula in the treatment of asthenospermia[D]. Nanjing: Nanjing University of Chinese Medicine, 2022.
[14]	王靖雅. 黑龙江产小粒菟丝子拟雌激素作用质量标志物的初步发现及质量控制[D]. 哈尔滨:哈尔滨商业大学, 2018. [WANG J Y. Preliminary discovery and quality control of quality markers of estrogenic effects of Cuscuta chinensis from Heilongjiang province[D]. Harbin:Harbin University of Commerce, 2018.] WANG J Y. Preliminary discovery and quality control of quality markers of estrogenic effects of Cuscuta chinensis from Heilongjiang province[D]. Harbin: Harbin University of Commerce, 2018.
[15]	宋辉, 黄晓俏, 孙向明, 等. 基于网络药理学、分子对接和动物实验探讨菟丝子醇提物抗乳腺癌作用机制[J]. 中草药,2024,55(14):4747−4758. [SONG H, HUANG X Q, SUN X M, et al. Mechanism of alcohol extract of Cuscuta chinensis against breast cancer based on network pharmacology, molecular docking and animal experiments[J]. Chinese Traditional and Herbal Drugs,2024,55(14):4747−4758.] SONG H, HUANG X Q, SUN X M, et al. Mechanism of alcohol extract of Cuscuta chinensis against breast cancer based on network pharmacology, molecular docking and animal experiments[J]. Chinese Traditional and Herbal Drugs, 2024, 55（14）: 4747−4758.
[16]	孙向明, 宋辉, 阎新佳, 等. 菟丝子雌激素样作用质量标志物的筛选及含量测定[J]. 中草药,2020,51(10):2671−2679. [SUN X M, SONG H, YAN X J, et al. Screening and determination of estrogen-like quality markers of Cuscuta chinensis[J]. Chinese Traditional and Herbal Drugs,2020,51(10):2671−2679.] doi: 10.7501/j.issn.0253-2670.2020.10.010 SUN X M, SONG H, YAN X J, et al. Screening and determination of estrogen-like quality markers of Cuscuta chinensis[J]. Chinese Traditional and Herbal Drugs, 2020, 51（10）: 2671−2679. doi: 10.7501/j.issn.0253-2670.2020.10.010
[17]	周文月, 文艺儒, 周森林, 等. 基于网络药理学及体外实验探讨人参-甘草对非小细胞肺癌的作用机制[J]. 食品工业科技,2023,44(16):25−33. [ZHOU W Y, WEN Y R, ZHOU S L, et al. Study on the mechanism of ginseng and liquorice on non-small cell lung cancer based on network pharmacology and in vitro experiments[J]. Science and Technology of Food Industry,2023,44(16):25−33.] ZHOU W Y, WEN Y R, ZHOU S L, et al. Study on the mechanism of ginseng and liquorice on non-small cell lung cancer based on network pharmacology and in vitro experiments[J]. Science and Technology of Food Industry, 2023, 44（16）: 25−33.
[18]	蔡春梅, 黄玉叶, 李丽燕, 等. 黄芩提取物抗UVA诱导NIH3T3细胞光老化的作用[J]. 食品工业科技,2024,45(12):327−333. [CAI C M, HUANG Y Y, LI L Y, et al. Scutellaria baicalensis extract inhibits the UVA-induced photoaging in NIH3T3 cells[J]. Science and Technology of Food Industry,2024,45(12):327−333.] CAI C M, HUANG Y Y, LI L Y, et al. Scutellaria baicalensis extract inhibits the UVA-induced photoaging in NIH3T3 cells[J]. Science and Technology of Food Industry, 2024, 45（12）: 327−333.
[19]	程学云, 胡光耀, 刘红丽, 等. 巴马汀抑制人口腔癌KB细胞迁移、侵袭及上皮间充质转化的研究[J]. 中国临床药理学杂志,2024,40(12):1749−1753. [CHENG X Y, HU G Y, LIU H L, et al. Effect of palmatine inhibiting migration, invasion and epithelial mesenchymal transformation in human oral cancer KB cells[J]. The Chinese Journal of Clinical Pharmacology,2024,40(12):1749−1753.] CHENG X Y, HU G Y, LIU H L, et al. Effect of palmatine inhibiting migration, invasion and epithelial mesenchymal transformation in human oral cancer KB cells[J]. The Chinese Journal of Clinical Pharmacology, 2024, 40（12）: 1749−1753.
[20]	马永超, 程琦, 吴华, 等. 基于Nrf2/ROS信号通路探讨岩藻多糖对食管癌细胞增殖的抑制作用[J]. 食品工业科技,2024,45(11):316−322. [MA Y C, CHENG Q, WU H, et al. Inhibition of proliferation of esophageal cancer cells by fucoidan based on Nrf2/ROS signaling pathway[J]. Science and Technology of Food Industry,2024,45(11):316−322.] MA Y C, CHENG Q, WU H, et al. Inhibition of proliferation of esophageal cancer cells by fucoidan based on Nrf2/ROS signaling pathway[J]. Science and Technology of Food Industry, 2024, 45（11）: 316−322.
[21]	朱扶蓉, 邓元荣, 何舒澜, 等. 闽产重瓣铁线莲总皂苷对人食管癌EC-9706细胞荷瘤裸鼠抗肿瘤作用[J]. 中国中西医结合杂志,2021,41(9):1107−1112. [ZHU F R, DENG Y R, HE S L, et al. Effect of total saponins from Clematis Florida var. Plena D. on Xenograft tumors derived from human esophageal carcinoma cell line EC9706 in nude mice[J]. Chinese Journal of Integrated Traditional and Western Medicine,2021,41(9):1107−1112.] ZHU F R, DENG Y R, HE S L, et al. Effect of total saponins from Clematis Florida var. Plena D. on Xenograft tumors derived from human esophageal carcinoma cell line EC9706 in nude mice[J]. Chinese Journal of Integrated Traditional and Western Medicine, 2021, 41（9）: 1107−1112.
[22]	尧智军. CSMD2通过调控PI3K/AKT信号通路促进膀胱癌增殖及进展的作用及机制研究[D]. 南昌:南昌大学, 2024. [YAO Z J. The mechanism of CSMD2 promoting the proliferation and progression of bladder cancer by regulating PI3K/AKT signal pathway[D]. Nanchang:Nanchang University, 2024.] YAO Z J. The mechanism of CSMD2 promoting the proliferation and progression of bladder cancer by regulating PI3K/AKT signal pathway[D]. Nanchang: Nanchang University, 2024.
[23]	KETELUT-CARNEIRO N, FITZGERALD K A. Apoptosis, pyroptosis, and necroptosis-Oh my! The many ways a cell can die[J]. J Mol Biol,2022,434(4):167378. doi: 10.1016/j.jmb.2021.167378
[24]	MORANA O, WOOD W, GREGORY C D. The apoptosis paradox in cancer[J]. Int J Mol Sci,2022,23(3):1328. doi: 10.3390/ijms23031328
[25]	IDRISS H T, NASMITH J H. TNF alpha and the TNF receptor superfamily:Structure-function relationship(s)[J]. Microsc Res Tech,2000,50(3):184−195. doi: 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H
[26]	LIU Z W, ZHANG Y M, ZHANG L Y, et al. Duality of interactions between TGF-β and TNF-α during tumor formation. front immunol[J]. Front Immunol,2022,12:810286. doi: 10.3389/fimmu.2021.810286
[27]	ABBAS A K, TROTTA E, R S D, et al. Revisiting IL-2:Biology and therapeutic prospects[J]. Sci Immunol,2018,3(25):eaat1482. doi: 10.1126/sciimmunol.aat1482
[28]	WIDODO S S, DINEVSKA M, FURST L M, et al. IL-10 in glioma[J]. Br J Cancer,2021,125(11):1466−1476. doi: 10.1038/s41416-021-01515-6
[29]	LI B, ZHANG W, GUO C, et al. Benchmarking spatial and single-cell transcriptomics integration methods for transcript distribution prediction and cell type deconvolution[J]. Nat Methods,2022,19(6):662−670. doi: 10.1038/s41592-022-01480-9
[30]	DRIES R, CHEN J, DEL R N, et al. Advances in spatial transcriptomic data analysis[J]. Genome Res,2021,31(10):1706−1718. doi: 10.1101/gr.275224.121
[31]	梁鸿艺, 刘志勇, 刘晓菲, 等. 基于PI3K/Akt/HIF-1α信号通路探讨补肾活血汤干预乳腺癌内分泌治疗相关骨质疏松的作用机制[J]. 中国实验方剂学杂志,2022,28(17):164−172. [LIANG H Y, LIU Z Y, LIU X F, et al. Intervention mechanism of Bushen Huoxuetang on osteoporosis related to endocrine therapy in breast cancer based on PI3K/Akt/HIF-1α signaling pathway[J]. Chinese Journal of Experimental Traditional Medical Formulae,2022,28(17):164−172.] LIANG H Y, LIU Z Y, LIU X F, et al. Intervention mechanism of Bushen Huoxuetang on osteoporosis related to endocrine therapy in breast cancer based on PI3K/Akt/HIF-1α signaling pathway[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2022, 28（17）: 164−172.
[32]	ALINEJAD V, DOLATI S, MOTALLEBNEZHAD M, et al. The role of IL17B-IL17RB signaling pathway in breast cancer[J]. Biomed Pharmacother. 2017, 88:795-803. ].
[33]	ZHANG X, SHEN T, ZHOU X, et al. Network pharmacology based virtual screening of active constituents of Prunella vulgaris L. and the molecular mechanism against breast cancer[J]. Sci Rep,2020,10(1):15730. doi: 10.1038/s41598-020-72797-8
[34]	刘晓燕, 龙凤, 赵玉, 等. 基于PI3K/Akt/GSK-3β通路探讨蒲公英多糖对三阴性乳腺癌细胞迁移和侵袭的影响[J]. 天然产物研究与开发,2023,35(7):1135−1143. [LIU X Y, LONG F, ZHAO Y, et al. Effect of dandelion polysaccharide on migration and invasion of triple-negative breast cancer cells based on[J]. Natural Product Research and Development,2023,35(7):1135−1143.] LIU X Y, LONG F, ZHAO Y, et al. Effect of dandelion polysaccharide on migration and invasion of triple-negative breast cancer cells based on[J]. Natural Product Research and Development, 2023, 35（7）: 1135−1143.
[35]	KNUTTI N, HUBER O, FRIEDRICH K. CD147 (EMMPRIN) controls malignant properties of breast cancer cells by interdependent signaling of Wnt and JAK/STAT pathways[J]. Mol Cell Biochem,2019,451(1-2):197−209. doi: 10.1007/s11010-018-3406-9
[36]	TANEJA N, CHAUHAN A, KULSHRESHTHA R, et al. HIF-1 mediated metabolic reprogramming in cancer:Mechanisms and therapeutic implications[J]. Life Sci,2024,352:122890. doi: 10.1016/j.lfs.2024.122890
[37]	李志国. 抗纤抑癌方治疗肝癌前病变的疗效观察及作用机制研究[D]. 北京:北京中医药大学, 2021. [LI Z G. Study on the therapeutic efficacy and mechanism of effect of Kangxian-Yiai formula in the treatment of precancerous lesions of liver cancer[D]. Beijing:Beijing University of Chinese Medicine, 2021.] LI Z G. Study on the therapeutic efficacy and mechanism of effect of Kangxian-Yiai formula in the treatment of precancerous lesions of liver cancer[D]. Beijing: Beijing University of Chinese Medicine, 2021.
[38]	INFANTINO V, SANTARSIERO A, CONVERTINI P, et al. Cancer cell metabolism in hypoxia:Role of HIF-1 as key regulator and therapeutic target[J]. Int J Mol Sci,2021,22(11):5703. doi: 10.3390/ijms22115703
[39]	DELEYTO-SELDAS N, EFEYAN A. The mTOR-autophagy axis and the control of metabolism[J]. Front Cell Dev Biol,2021,9:655731. doi: 10.3389/fcell.2021.655731
[40]	TU Z J, HU G Y, LI Q B. Research progress of p70 ribosomal protein S6 kinase inhibitors[J]. Acta Pharm Sin,2015,50(3):261−271.
[41]	MAO B, ZHANG Q, MA L, et al. Overview of research into mTOR inhibitors[J]. Molecules,2022,27(16):5295. doi: 10.3390/molecules27165295
[42]	方炜丹. G蛋白偶联受体GPRC5A、NPSR1促进胰腺癌细胞增殖、迁移、侵袭的功能及分子机制[D]. 南昌:南昌大学, 2024. [FANG W D. The roles and molecular mechanism of G protein-coupled receptors GPRC5A and NPSR1 on cell proliferation, migration and invasion in pancreatic cancer cells[D]. Nanchang:Nanchang University, 2024.] FANG W D. The roles and molecular mechanism of G protein-coupled receptors GPRC5A and NPSR1 on cell proliferation, migration and invasion in pancreatic cancer cells[D]. Nanchang: Nanchang University, 2024.

Supplements (0)

Get Citation

PDF

XML

Article Metrics

Article views (18) PDF downloads (7)

Science and Technology of Food Industry

Inhibition of Proliferation of 4T1 Breast Cancer Cells by Cuscuta Alcohol Extract Based on mTOR/HIF-1α/VEGF Signaling Pathway

Abstract

References

Catalog

Article Metrics

Export File

Citation

Format

Content